MEMPHASYS LIMITED. — Capital/Financing Update 2019

Apr 4, 2019

==> picture [222 x 64] intentionally omitted <==

ASX Release 5[th] April 2019

Monash IVF takes equity stake in Memphasys

Highlights

• Monash IVF and Memphasys continue to work collaboratively towards commercial product launch of the Felix device

• Under terms of Collaboration Agreement Memphasys has issued shares to Monash IVF in leu of services provided

• Monash IVF retains right to utilise the Felix device in Monash IVF clinics for a 12month period when it becomes commercially available.

Australian-based bio-separations company Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is pleased to provide an update regarding a Collaborative Agreement (see ASX Announcement 18 September 2018) with Monash IVF to advance the Company’s Felix device - a unique technology for separating the most viable sperm in a semen sample for use in human IVF.

Monash IVF clinicians and researchers have, since early 2018, provided advice on the design and operation of the new Felix device to be marketed to IVF clinics globally. In particular, they have been working with Memphasys in testing and providing feedback on the operation of the current Felix prototype device.

As per the Collaboration Agreement, and in leu of consulting fees for services provided, they have been issued with 4m ordinary MEM shares, at an issue price of 2c.

Commenting on the Collaborative Agreement and the issue of shares to Monash IVF, Memphasys Executive Chairman, Alison Coutts, said:

“The Felix device, which has been developed with the assistance of world-renowned fertility expert Professor John Aitken has benefitted considerably from the team at Monash IVF who are highly experienced at commercialising innovative in-vitro fertilisation technologies.

The Collaborative Agreement has also allowed us to fast-track development as the Company meets its milestones and progresses commercialisation, most notably through the imminent testing of the Felix device through our network of international Key Opinion Leaders.

“Having Monash IVF aligned to our success is of benefit to all shareholders.” she said.

ENDS

For further information please contact:

Alison Coutts	David Tasker
Executive Chairman	Managing Director
Memphasys Limited	Chapter One Advisors
T: +61 2 8415 7300	T: +0433 112 936
E:alison.coutts@memphasys.com	E:dtasker@chapteroneadvisors.com.au

1

– 2 –

About Memphasys:

Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company’s patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.

– 3 –

Appendix

Felix product development and commercialisation timeline

==> picture [464 x 340] intentionally omitted <==

Note: The dates on the table are indicative only, reflecting what Memphasys currently expects will be the most likely commercialisation milestone timeframes.